WO/2014/192284 PEPTIDE COMPOUND||WO||04.12.2014|
||PCT/JP2014/002772||TAKEDA PHARMACEUTICAL COMPANY LIMITED ||ASAMI, Taiji |
The present invention provides a novel peptide compound having an activating action on GLP-1 receptors and GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a partial sequence represented by the formula (I) or a salt thereof and a medicament comprising the same are provided. P1-Tyr-Aib-Glu-Gly-Thr-alphaMePhe-Thr-Ser-Asp-Tyr-A11-A12-A13-Leu-Asp-A16-A17-Ala-Gln-A20-Glu-Phe-Val-Lys-Trp-Leu-Leu-Lys-A29 (I) wherein each symbol is as defined herein.
WO/2014/180840 APPARATUS AND METHOD FOR READING A DOCUMENT AND PRINTING A MARK THEREON||WO||13.11.2014|
||PCT/EP2014/059227||SICPA HOLDING SA ||TALWERDI, Mehdi |
An apparatus for verifying whether a user of an object is an authorized user of the object includes: (a) means for detecting a biometric feature of the user and generating data representing the biometric feature; and (b) a reader- printer for reading and printing on the object, which includes: (i) reader system for reading the object to obtain a digital representation of biometric information associated with the authorized user; and (ii) printer system for printing on the object; the apparatus being operable to cause the printer system to print on the object if the data matches the digital representation. Separately or incorporated into the apparatus, the reader-printer may include: (a) reader for reading the object to obtain a digital signature representing a unique feature of the object; and (b) printer for printing on the object if the digital signature matches a reference digital signature associated with the object.
WO/2014/177977 IMIDAZO-TRIAZINE DERIVATIVES AS PDE10 INHIBITORS||WO||06.11.2014|
||PCT/IB2014/060945||PFIZER INC. ||CHAPPIE, Thomas, Allen |
The present invention is directed to a new class of triazine derivatives as described by formula (I) below in which A, X, R1, R2, R3, and R4 are as defined herein and to the use of the compounds as PDE10 inhibitors.
WO/2014/174524 A NOVEL COMPOSITION FOR NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)||WO||30.10.2014|
||PCT/IN2013/000391||CADILA HEALTHCARE LIMITED ||PATEL, Pankaj |
The present invention provides a compound of Formula (I) or pharmaceutical acceptable thereof, wherein 'R' is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (I) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (NAFLD) including fatty liver (steatosis), nonalcoholic steatohepatitis (NASH), and cirrhosis (advanced scarring of the liver).
WO/2014/166996 METHOD AND DEVICE FOR COVERING AND WATERPROOFING JOINTS IN HYDRAULIC WORKS||WO||16.10.2014|
||PCT/EP2014/057153||CARPI TECH B.V. ||SCUERO, Alberto Maria |
A method and a device for covering and waterproofing joints between concrete members (12, 14) of hydraulic works, such as dams, canals, hydraulic galleries and reservoirs. A flexible cover strip (17) comprising a flexible waterproofing membrane (21) in elastomeric material having a first elastic modulus (E1), and at least one flexible support layer (23) in synthetic material having a second elastic modulus (E2) greater than the first elastic modulus (E1) for limiting deformation of the impermeable membrane (21), is straddled between the opposite concrete members (12, 14), for example at vertical joints and/or at longitudinal joints of the hydraulic work. The support layer (23) and the waterproofing membrane (21) are transversely folded in a loop and laid down inside and/or outside the joint sealingly fastening the cover strip (17) to the concrete members (12, 14) along the edges thereof. Movements between concrete members (12, 14) of the joint (16) are compensated by a free extension of the folded cover strip (17).
WO/2014/164187 CRYSTALLINE FORM OF A SUBSTITUTED THIAZOLYLACETIC ACID TRIETHYLAMINE SALT||WO||09.10.2014|
||PCT/US2014/021080||THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC ||ZHANG, Weijiang |
The invention relates to a crystalline form of a triethylai salt of (2Z)-2-(2-amino-5-chlorothiazol-4-yl)-2-(3-N-tert- butoxycarbonylaminopropoxyimino)acetic acid. (I) The invention also relates to processes and intermediates for preparing the crystalline form. The crystalline form is useful as an intermediate for preparing cross-linked glycopeptide-cephalosporin antibiotics.
WO/2014/161595 USE OF PIDOTIMOD TO TREAT INFLAMMATORY BOWEL DISEASE||WO||09.10.2014|
||PCT/EP2013/057208||POLICHEM SA ||MAILLAND, Federico |
The present invention is directed to the use of pidotimod, or a physiologically acceptable salt thereof, to treat inflammatory bowel disease. For the treatment of the present invention, pidotimod, or a physiologically acceptable salt thereof, may be administered either by oral route or rectally.
WO/2014/164558 PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES||WO||09.10.2014|
||PCT/US2014/022801||TAKEDA PHARMACEUTICAL COMPANY LIMITED ||LAWSON, John David |
Disclosed are compounds of Formula 1, or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.
WO/2014/165779 DRUG COMBINATIONS TO TREAT CANCER||WO||09.10.2014|
||PCT/US2014/033008||EXELIXIS, INC. ||SWEENEY, Christopher J. |
This invention relates to the combination of cabozantinib and abiraterone to treat cancer, particularly castration resistant prostate cancer.
WO/2014/161594 USE OF PIDOTIMOD TO TREAT IRRITABLE BOWEL SYNDROME||WO||09.10.2014|
||PCT/EP2013/057205||POLICHEM SA ||MAILLAND, Federico |
The present invention is directed to the use of pidotimod, or a physiologically acceptable salt thereof, to treat irritable bowel syndrome. For the treatment of the present invention, pidotimod, or a physiologically acceptable salt thereof, may be administered either by oral route or rectally.